SEARCH

SEARCH BY CITATION

References

  • 1
    Kanj SS, Sharara AI, Clavien PA, Hamilton JD. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis 1996; 22: 537549.
  • 2
    Stratta RJ, Shaeffer MS, Markin RS, Wood RP, Langnas AN et al. Cytomegalovirus infection and disease after liver transplantation, an overview. Dig Dis Sci 1992; 37: 673688.
  • 3
    Gane E, Saliba F, Valdecasas GJC, O'Grady J, Pescovitz MD, Lyman S, Robinson CA. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997; 350: 17291733.
  • 4
    Singh N, Gayowski T, Wagener MM, Cacciarelli T. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset CMV disease. Transplantation 2005; 79: 8590.
  • 5
    Rayes N, Oettle H, Schmidt CA, Lohmann R, Steinmûller T, Bechstein WO, Neuhaus P. Preemptive therapy in CMV-antigen positive patients after liver transplantation — a prospective trial. Ann Transpl 1999; 4: 1217.
  • 6
    Portela D, Patel R, Larson-Keller JJ, Ilstrup DM, Weisner RI, Steers JI, et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995; 171: 10141018.
  • 7
    Van der BW, Speich R. Management of cytomegalovirus infection and disease after solid organ transplantation. Clin Infect Dis 2001; 33: S32S37.
  • 8
    Green M, Avery RK, Preiksaitis J. Guidelines for the prevention and management of infectious complications of solid organ transplantation. Multiply resistant gram-positive bacteria. Am J Transpl 2004; 4: 3136.
  • 9
    Gayowski T, Marino IR, Singh N, Doyle H, Wagener MM, Fung JJ, Starzl TE. Orthotopic liver transplantation in high risk patients: risk factors associated with mortality and infectious morbidity. Transplantation 1997; 65: 499504.
  • 10
    Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients, a randomized trial. Ann Int Med 1994; 120: 375381.
  • 11
    Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Cyomegalovirus antigenemia directed preemptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus diseases in liver transplant recipients: a randomized, controlled trial. Transplantation 2000; 70: 717712.
  • 12
    Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions of nosocomial infections. Am J Inf Control 1988; 16: 128140.
  • 13
    Kusne S, Dummer JS, Singh N, Iwatsuki S, Makowka L, Esquivel C, et al. Infections after liver transplantation, an analysis of 101 consecutive cases. Medicine 1988; 67: 132143.
  • 14
    Singh N, Gayowski T, Wagener M, Yu VL. Infectious complications in liver recipients on tacrolimus: prospective analysis of 88 consecutive liver transplants. Transplantation 1994; 58: 774778.
  • 15
    Grundy JE, Lui SF, Super M, Berry NJ, Sweny P, Fernando ON et al. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet 1988; 2: 132135.
  • 16
    Smiley ML, Wlodaver CG, Grossman RA, et. al. The role of pretransplant immunity in protection from cytomegalovirus disease following renal transplantation. Transplantation 1985; 40: 157161.
  • 17
    Mehra MR, Uber PA, Scott RL, Park MH. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. Transplantation 2002; 74: 15681573.
  • 18
    Roberts JP, Wolfe RA, Bragg-Gresham JL, Rush SH, Wynn JJ, Distant DA, et al. Effect of changing the priority for HLA matching on the rates and outcomes of kidney transplantation in minority groups. N Engl J Med 2004; 350: 545551.
  • 19
    Rogers J, Baliga PK, Chavin KD, Lin A, Emovon O, Afzal F, et al. Effect of ethnicity on outcome of simultaneous pancreas and kidney transplantation. Am J Transpl 2003; 3: 12781288.
  • 20
    Hardinger KL, Stratta RJ, Egidi MF, Alloway RR, Shokouh-Amiri M, Garber KW, et al. Renal allograft outcomes in African American versus Caucasian transplant recipients in the tacrolimus era. Surgery 2001; 130: 738747.
  • 21
    Vasquez EM, Benedetti E, Pollak R. Ethnic differences in clinical response to corticosteroid treatment of acute renal allograft rejection. Transplantation 2001; 71: 229233.
  • 22
    Isaacs RB, Nock SL, Spencer CE, Connors JrAF, Wang X-Q, Sawyer R, Lobo PI. Racial disparities in renal transplant outcomes. Am J Kidney Dis 1999; 34: 706712.
  • 23
    Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 1998; 65: 515523.
  • 24
    Opelz G, Mytilineos J, Scherer S, Wujciak T. Influence of HLA matching and DNA typing on kidney and heart transplant survival in Black recipients. Transpl Proceed 1997; 29: 33333335.
  • 25
    Ward FE, MacQueen JM. Immunogenetic factors that may contribute to ethnic differences in renal allograft survival. Clin Transpl 1996; 10: 620624.
  • 26
    Ciancio G, Burke GW, Suzart K, Mattiazzi A, Vaidya A, Roth D, et al. The use of daclizumab, tacrolimus and mycophenolate mofetil in African-American and Hispanic first renal transplant recipients. Am J Transpl 2003; 3: 10101016.
  • 27
    Mejia A, Halff GA, Esterl R, Cigarroa F, Speeg KV, Villarreal R, Washburn K. Outcome of liver transplantation in Hispanics versus Non-Hispanics: is there a difference? Transpl Proceed 2002; 34: 12361238.
  • 28
    Lemire J, Capparelli EV, Benador N, Grimm P, Macdonald D, Reznik V. Neoral pharmacokinetics in Latino and Caucasian pediatric renal transplant recipients. Pediatr Nephrol 2001; 16: 311314.
  • 29
    Meier-Kriesche H-U, Ojo A, Magee JC, Cibrik DM, Hanson JA, Leichtman AB, Kaplan B. African-American renal transplant recipients experience decreasd risk of death due to infection: possible implications for immunosuppressive strategies. Transplantation 2000; 70: 375379.
  • 30
    Creemers PC, Kahn D. A unique African HLA haplotype may identify a population at increased risk for kidney graft rejection. Transplantation 1998; 65: 285287.
  • 31
    Mañez R, White LT, Linden P, Kusne S, Maratin M, Kramer D, et al. The influence of HLA matching on cytomegalovirus hepatitis and chronic rejection after liver transplantation. Transplantation 1993; 55: 10671071.
  • 32
    Rogers J, Singh N, Carrigan DR, Rohal S, Kusne S, Knox KK, et al. Clinical relevance of human herpesvirus-6 infection in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and impact on outcome. Transplantation 2000; 69: 25662573.
  • 33
    Mutimer D, Mirza D, Shaw J, O'Donnell K, Elias E. Enhanced (cytomegalovirus) viral replication associated with septic bacterial complications in liver transplant recipients. Transplantation 1997; 63: 14111415.
  • 34
    Döcke WD, Prösch S, Fietze E, Kimel V, Zuckermann H, Klug C, et al. Cytomegalovirus reactivation and tumour necrosis factor. Lancet 1994; 343: 268269.
  • 35
    Stein J, Volk HD, Liebenthal C, Kruger DH, Prosch S. Tumour necrosis factor alpha stimulates the activity of the human cytomegalovirus major immediate early enhancer/promoter in immature monocytic cells. J Gen Virol 1993; 74: 2333.